Moderna Lifts 2026 Revenue Outlook on Vaccine Momentum
Moderna raised its 2026 revenue growth forecast to 15-25%, citing stronger uptake of its newer vaccine products.
Moderna has sharply upgraded its financial outlook for 2026, now projecting revenue growth of 15% to 25%, a significant jump from the company's earlier guidance that called for growth of up to 10%. The revision signals renewed confidence at the Cambridge, Massachusetts-based biotech firm after a period of post-pandemic recalibration.
The company's chief executive attributed the improved forecast to growing traction for its newer vaccine offerings, suggesting that diversification beyond its flagship COVID-19 product is beginning to show measurable commercial results. The scale of the guidance increase — as much as 15 percentage points above the prior ceiling — points to accelerating demand that management believes is sustainable heading into the following year.
Read more How the 'Endless Cruise' Odyssey Collapsed Despite Millions Spent →
The upgrade comes as the broader vaccine market remains competitive and as pharmaceutical companies wrestle with declining COVID booster uptake in many markets. Moderna's ability to revise guidance upward under those conditions may reflect early success in expanding its respiratory or other pipeline products, though the company did not detail which specific vaccines were driving the momentum.
For investors, the revised outlook represents a potentially meaningful inflection point after Moderna posted significant losses in recent years as pandemic-era revenue faded. Analysts will likely scrutinize whether the newer products can sustain the kind of volume needed to justify the raised targets as the year progresses.
Continue reading at Business News.
